ReviewBritish journal of clinical pharmacology2019

Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.

Julie A Stone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.